30 August 2024
30 August 2024
BioMarin announced plans to downsize its workforce as it updates the programme for its lead asset Roctavian.
Repare plans to slash the headcount in its preclinical group and reduce R&D activities as it funnels resources into clinical candidates.
Lindy Biosciences will receive a $20m upfront payment from Novartis and up to $934m in additional payments.
The vaccine approval is based on existing human safety data and animal study.
D3 LLC and DEEPCORE co-led the funding round.
The status could lead to seven years of marketing exclusivity in the US.
The recombinant adjuvanted RSV vaccine is indicated for those at increased disease risk.
TCBP earmarked the net proceeds from the offering to support key initiatives.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
